122 related articles for article (PubMed ID: 9839579)
21. Voided urine cytology is a useful tool predicting non-muscle-invasive bladder cancer risk before surgery.
Gómez Del Cañizo C; González Ginel I; Martín-Arriscado Arroba C; de la Calle Moreno A; Hernández Arroyo M; Rodríguez Antolín A; Guerrero Ramos F
Urol Oncol; 2024 Aug; 42(8):246.e15-246.e21. PubMed ID: 38664179
[TBL] [Abstract][Full Text] [Related]
22. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
[TBL] [Abstract][Full Text] [Related]
23. Urinary cytology in the detection of bladder tumours. Influence of concomitant urothelial atypia.
Harving N; Petersen SE; Melsen F; Wolf H
Scand J Urol Nephrol Suppl; 1989; 125():127-31. PubMed ID: 2633311
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group.
Ellis WJ; Blumenstein BA; Ishak LM; Enfield DL
Urology; 1997 Dec; 50(6):882-7. PubMed ID: 9426718
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
27. The value of exfoliative urine cytology in combination with flexible cystoscopy in the diagnosis of recurrent transitional cell carcinoma of the urinary bladder.
Loh CS; Spedding AV; Ashworth MT; Kenyon WE; Desmond AD
Br J Urol; 1996 May; 77(5):655-8. PubMed ID: 8689105
[TBL] [Abstract][Full Text] [Related]
28. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
[TBL] [Abstract][Full Text] [Related]
29. Utility of the BTA stat test kit for bladder cancer screening.
Nasuti JF; Gomella LG; Ismial M; Bibbo M
Diagn Cytopathol; 1999 Jul; 21(1):27-9. PubMed ID: 10405804
[TBL] [Abstract][Full Text] [Related]
30. Ta and T1 bladder cancer: location, recurrence and progression.
Heney NM; Nocks BN; Daly JJ; Prout GR; Newall JB; Griffin PP; Perrone TL; Szyfelbein WA
Br J Urol; 1982 Apr; 54(2):152-7. PubMed ID: 7082932
[TBL] [Abstract][Full Text] [Related]
31. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
32. [The significance of urine cytology three consecutive days after transurethral resection as a predictor of superficial bladder cancer recurrence].
Yumura Y; Takase K; Kato Y; Hamano A; Mikata K; Ogo Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Mar; 50(3):171-6. PubMed ID: 15148768
[TBL] [Abstract][Full Text] [Related]
33. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic efficacy of the combination of urine cytology, urine analysis and history in the follow-up of bladder carcinoma.
Meuleman EJ; Delaere KP
Br J Urol; 1988 Aug; 62(2):150-3. PubMed ID: 3408887
[TBL] [Abstract][Full Text] [Related]
35. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
[TBL] [Abstract][Full Text] [Related]
36. Urinary cytodiagnosis: can it have a different prognostic implication than a diagnostic test?
Chow NH; Tzai TS; Cheng HL; Chan SH; Lin JS
Urol Int; 1994; 53(1):18-23. PubMed ID: 7974880
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of urinary cytology in bladder tumor].
Shimizu T; Tsuchiya K; Uchida T; Kawada T; Satoh J
Nihon Hinyokika Gakkai Zasshi; 1992 Feb; 83(2):220-4. PubMed ID: 1556841
[TBL] [Abstract][Full Text] [Related]
38. Transferrin receptor expression in primary superficial human bladder tumours identifies patients who develop recurrences.
Smith NW; Strutton GM; Walsh MD; Wright GR; Seymour GJ; Lavin MF; Gardiner RA
Br J Urol; 1990 Apr; 65(4):339-44. PubMed ID: 2340368
[TBL] [Abstract][Full Text] [Related]
39. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma.
Badalament RA; Hermansen DK; Kimmel M; Gay H; Herr HW; Fair WR; Whitmore WF; Melamed MR
Cancer; 1987 Oct; 60(7):1423-7. PubMed ID: 3304614
[TBL] [Abstract][Full Text] [Related]
40. The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice.
Reading J; Hall RR; Parmar MK
Br J Urol; 1995 May; 75(5):604-7. PubMed ID: 7613798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
